SCHEMBL2300095

SCHEMBL2300095

O=C(O)Nc1nc2ccc(C(=O)c3ccccc3C(=O)Nc3ccc(F)c(Cl)c3)cc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 4/20 0.54
▸ BRAF P15056 4/20 0.54
▸ MAPT P10636 3/20 0.53
▸ CYP2C9 P11712 3/20 0.53
▸ CYP2C19 P33261 2/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ NR2E3 Q9Y5X4 5/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ LMNA P02545 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ FADS1 O60427 1/20 0.48
▸ ABL1 P00519 2/20 0.48
▸ MAOB P27338 1/20 0.48
▸ CYP1A2 P05177 2/20 0.47
▸ KDR P35968 2/20 0.47
▸ ABCC4 O15439 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857512 0.90 RAF1 (0.66) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL2297881 0.90 RAF1 (0.58) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL2299039 0.89 RAF1 (0.54) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL3475822 0.88 RAF1 (0.59) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL2357346 0.87 RAF1 (0.54) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL2299292 0.86 RAF1 (0.55) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL3471881 0.86 RAF1 (0.59) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL1469018 0.84 MAPT (0.50) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL2296483 0.83 RAF1 (0.56) RAF1BRAFMAPTCYP2C9CYP2C19
SCHEMBL2357955 0.83 RAF1 (0.63) RAF1BRAFMAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback